UCP1 and obesity due to melanocortin 4 receptor deficiency: Therefore, it is possible that novel therapeutic agents activating or elevating the expression of PGC-1α and UCP1 would have crucial impacts on increasing the energy expenditure to ultimately prevent obesity.